These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 33173046)

  • 1. Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors.
    Wang H; Najibi AJ; Sobral MC; Seo BR; Lee JY; Wu D; Li AW; Verbeke CS; Mooney DJ
    Nat Commun; 2020 Nov; 11(1):5696. PubMed ID: 33173046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
    Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K
    Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant
    Deng W; Lira V; Hudson TE; Lemmens EE; Hanson WG; Flores R; Barajas G; Katibah GE; Desbien AL; Lauer P; Leong ML; Portnoy DA; Dubensky TW
    Proc Natl Acad Sci U S A; 2018 Aug; 115(32):8179-8184. PubMed ID: 30038013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
    Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
    Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation.
    Lee SJ; Song L; Yang MC; Mao CP; Yang B; Yang A; Jeang J; Peng S; Wu TC; Hung CF
    Vaccine; 2015 Mar; 33(13):1549-55. PubMed ID: 25701675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
    Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
    Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
    Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
    Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
    Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
    J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers.
    Shen L; Li J; Liu Q; Song W; Zhang X; Tiruthani K; Hu H; Das M; Goodwin TJ; Liu R; Huang L
    ACS Nano; 2018 Oct; 12(10):9830-9841. PubMed ID: 30253648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of two different immunotherapies on triple negative breast cancer in animal model.
    Liu X; Hu J; Cao W; Qu H; Wang Y; Ma Z; Li F
    Cell Immunol; 2013; 284(1-2):111-8. PubMed ID: 23973874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic Cells Pulsed with Cytokine-Adjuvanted Tumor Membrane Vesicles Inhibit Tumor Growth in HER2-Positive and Triple Negative Breast Cancer Models.
    Munoz LE; Monterroza L; Bommireddy R; Shafizadeh Y; Pack CD; Ramachandiran S; Reddy SJC; Selvaraj P
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis.
    Rao L; Wu L; Liu Z; Tian R; Yu G; Zhou Z; Yang K; Xiong HG; Zhang A; Yu GT; Sun W; Xu H; Guo J; Li A; Chen H; Sun ZJ; Fu YX; Chen X
    Nat Commun; 2020 Sep; 11(1):4909. PubMed ID: 32999291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ vaccination with biocompatibility controllable immuno-sensitizer inducing antitumor immunity.
    Shin H; Na K
    Biomaterials; 2019 Mar; 197():32-40. PubMed ID: 30639548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells.
    Shimizu K; Yamasaki S; Shinga J; Sato Y; Watanabe T; Ohara O; Kuzushima K; Yagita H; Komuro Y; Asakura M; Fujii S
    Cancer Res; 2016 Jul; 76(13):3756-66. PubMed ID: 27371739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Yamaue H
    Int J Oncol; 2007 Oct; 31(4):931-9. PubMed ID: 17786327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.